Eric Venker Sells 315,522 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 315,522 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the sale, the chief operating officer now owns 959,457 shares of the company’s stock, valued at $10,611,594.42. The trade was a 24.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.65, for a total value of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00.

Roivant Sciences Trading Down 1.5 %

NASDAQ ROIV opened at $10.67 on Wednesday. The company has a market capitalization of $7.61 billion, a PE ratio of -71.13 and a beta of 1.26. Roivant Sciences Ltd. has a 1-year low of $9.96 and a 1-year high of $13.06. The firm’s fifty day simple moving average is $10.78 and its 200-day simple moving average is $11.44.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Institutional Trading of Roivant Sciences

Several large investors have recently added to or reduced their stakes in ROIV. Norges Bank acquired a new stake in shares of Roivant Sciences in the 4th quarter valued at $52,443,000. TOMS Capital Investment Management LP bought a new position in Roivant Sciences during the third quarter valued at about $46,333,000. Invesco Ltd. boosted its stake in shares of Roivant Sciences by 49.7% during the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company’s stock worth $112,563,000 after acquiring an additional 3,159,603 shares in the last quarter. FMR LLC boosted its stake in shares of Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after acquiring an additional 2,593,910 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after acquiring an additional 2,404,232 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ROIV has been the topic of several research analyst reports. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $17.10.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.